Playback speed
10 seconds
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
The video connection was lost, please confirm you are connected to the internet
Error Code: MEDIA_ERR_NETWORK
Technical details
:
HLS playlist request error at URL: https://manifest.prod.boltdns.net/manifest/v1/hls/v4/clear/6057940559001/bdc1b22d-223f-44d9-abae-5457fd444585/10s/master.m3u8?fastly_token=Njc3ODQxZjFfNWZhYjM4ODhkZTYzZDAxYmEwYjdhZjgwODU1NmE4MDI1ODFmYmQ2MGEyZmMxMGY5M2E0NzZlMzY3NzY3YTUzZA%3D%3D.
Session ID: 2025-01-03:f1e4f883a3bde5881b134092 Player Element ID: vjs_video_3
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
0 views
July 24, 2024
In this video, Dr. Joyce O’Shaughnessy shares her expertise on the standard of care first-line treatment for patients with HR+, HER2- MBC and the efficacy and safety data for CDK4/6 inhibitors in this setting.
To access additional videos and download free resources, click here.
VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.
Comments are disabled for this content.